Strs Ohio Buys Shares of 47,700 Repligen Corporation $RGEN

Key Points

• Strs Ohio has acquired 47,700 shares of Repligen Corporation, valued at approximately $6.07 million, representing about 0.08% ownership in the company.
• Recent analysts' ratings show a mix of evaluations for Repligen, with eight investment analysts issuing a Buy rating and four a Hold rating, while the average price target is set at $166.67.
• Repligen's stock recently declined by 5.0%, currently trading at $113.54, following a quarterly earnings report that missed analysts' expectations.

Strs Ohio purchased a new stake in Repligen Corporation (NASDAQ:RGEN - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 47,700 shares of the biotechnology company's stock, valued at approximately $6,069,000. Strs Ohio owned about 0.08% of Repligen as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Quantinno Capital Management LP increased its stake in Repligen by 80.0% during the fourth quarter. Quantinno Capital Management LP now owns 3,523 shares of the biotechnology company's stock worth $507,000 after acquiring an additional 1,566 shares during the last quarter. ProShare Advisors LLC increased its stake in Repligen by 7.4% during the fourth quarter. ProShare Advisors LLC now owns 2,438 shares of the biotechnology company's stock worth $351,000 after acquiring an additional 167 shares during the last quarter. Polar Asset Management Partners Inc. increased its stake in Repligen by 76.9% during the fourth quarter. Polar Asset Management Partners Inc. now owns 6,900 shares of the biotechnology company's stock worth $993,000 after acquiring an additional 3,000 shares during the last quarter. Raiffeisen Bank International AG purchased a new position in shares of Repligen during the fourth quarter worth $29,000. Finally, Two Sigma Advisers LP boosted its position in shares of Repligen by 6.7% during the fourth quarter. Two Sigma Advisers LP now owns 134,800 shares of the biotechnology company's stock worth $19,403,000 after buying an additional 8,500 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on RGEN. Wall Street Zen lowered Repligen from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. Wells Fargo & Company lowered their price target on Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research report on Wednesday, July 30th. Barclays began coverage on Repligen in a research report on Tuesday, June 24th. They set an "overweight" rating and a $150.00 price target for the company. Stephens upgraded Repligen to an "overweight" rating and set a $160.00 price target for the company in a research report on Tuesday, July 22nd. Finally, Royal Bank Of Canada restated an "outperform" rating and set a $205.00 price target on shares of Repligen in a research report on Tuesday, September 2nd. Eight investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Repligen currently has a consensus rating of "Moderate Buy" and an average price target of $166.67.

Repligen Stock Down 5.0%

Shares of NASDAQ RGEN opened at $113.54 on Monday. The stock has a market cap of $6.39 billion, a P/E ratio of -454.14, a PEG ratio of 2.09 and a beta of 1.07. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $182.52. The business's fifty day simple moving average is $120.73 and its 200-day simple moving average is $127.58.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). The business had revenue of $182.37 million for the quarter, compared to analysts' expectations of $174.62 million. Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The firm's quarterly revenue was up 14.8% on a year-over-year basis. During the same period last year, the firm earned $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, equities analysts predict that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Insider Transactions at Repligen

In other Repligen news, Director Martin D. Madaus purchased 1,800 shares of the firm's stock in a transaction on Friday, August 8th. The stock was bought at an average cost of $112.13 per share, with a total value of $201,834.00. Following the acquisition, the director directly owned 1,800 shares of the company's stock, valued at approximately $201,834. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.20% of the stock is owned by company insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.